Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28471538 | 1.00 | PIK3C3 (0.39) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL30823279 | 1.00 | PIK3C3 (0.39) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL22635848 | 0.91 | IRAK4 (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL21187357 | 0.91 | IRAK4 (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL21187365 | 0.87 | PIK3C3 (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL30823273 | 0.87 | PIK3C3 (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL21177873 | 0.87 | PIK3C3 (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL16091613 | 0.87 | PDE10A (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL21279021 | 0.87 | PDE10A (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 | |
| SCHEMBL17750560 | 0.86 | PDE10A (0.38) | PIK3C3PDE10ATBK1IKBKEJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PIK3C3 1839/4885PDE10A 1271/4885TBK1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.